Savara Shares Slide After FDA Declines Drug Application

Dow Jones

May 27, 2025

By Katherine Hamilton

Savara shares fell after the Food and Drug Administration said its drug is not ready for a full review.

The stock dropped 35% to $1.85 in pre-market trading Tuesday.

The Langhorne, Pa., biopharmaceutical company said Tuesday it received a refusal-to-file letter from the FDA for the biologics license application for Molbreevi as a therapy to treat patients with autoimmune pulmonary alveolar proteinosis.

The FDA determined the license application, which was submitted in March, was not sufficiently complete and needed additional data on chemistry, manufacturing and controls. The refusal to file was not the result of safety concerns and the FDA did not request additional efficacy studies, Savara said.

Savara plans to request a Type A meeting with the FDA within the next 30 days. It is currently generating the data requested by the FDA, and expects to resubmit its application in the fourth quarter of 2025, CHief Executive Matt Pauls said.

The letter does not impact previous designations granted by regulators by Molbreevi.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

May 27, 2025 08:56 ET (12:56 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2538469262"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538469262\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2538469262?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-27 20:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538469262","market":"sh","top_or_hot":-1,"title":"Savara Shares Slide After FDA Declines Drug Application","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  Savara shares fell after the Food and Drug Administration said its drug is not ready for a full review. \n</p>\n<p>\n  The stock dropped 35% to $1.85 in pre-market trading Tuesday. \n</p>\n<p>\n  The Langhorne, Pa., biopharmaceutical company said Tuesday it received a refusal-to-file letter from the FDA for the biologics license application for Molbreevi as a therapy to treat patients with autoimmune pulmonary alveolar proteinosis. \n</p>\n<p>\n  The FDA determined the license application, which was submitted in March, was not sufficiently complete and needed additional data on chemistry, manufacturing and controls. The refusal to file was not the result of safety concerns and the FDA did not request additional efficacy studies, Savara said. \n</p>\n<p>\n  Savara plans to request a Type A meeting with the FDA within the next 30 days. It is currently generating the data requested by the FDA, and expects to resubmit its application in the fourth quarter of 2025, CHief Executive Matt Pauls said. \n</p>\n<p>\n  The letter does not impact previous designations granted by regulators by Molbreevi. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 27, 2025 08:56 ET (12:56 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Savara Shares Slide After FDA Declines Drug Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSavara Shares Slide After FDA Declines Drug Application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-27 20:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  Savara shares fell after the Food and Drug Administration said its drug is not ready for a full review. \n</p>\n<p>\n  The stock dropped 35% to $1.85 in pre-market trading Tuesday. \n</p>\n<p>\n  The Langhorne, Pa., biopharmaceutical company said Tuesday it received a refusal-to-file letter from the FDA for the biologics license application for Molbreevi as a therapy to treat patients with autoimmune pulmonary alveolar proteinosis. \n</p>\n<p>\n  The FDA determined the license application, which was submitted in March, was not sufficiently complete and needed additional data on chemistry, manufacturing and controls. The refusal to file was not the result of safety concerns and the FDA did not request additional efficacy studies, Savara said. \n</p>\n<p>\n  Savara plans to request a Type A meeting with the FDA within the next 30 days. It is currently generating the data requested by the FDA, and expects to resubmit its application in the fourth quarter of 2025, CHief Executive Matt Pauls said. \n</p>\n<p>\n  The letter does not impact previous designations granted by regulators by Molbreevi. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 27, 2025 08:56 ET (12:56 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2538469262","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538469262","pubTimestamp":1748350560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Savara shares fell after the Food and Drug Administration said its drug is not ready for a full review.The stock dropped 35% to $1.85 in pre-market trading Tuesday.The Langhorne, Pa., biopharmaceutical company said Tuesday it received a refusal-to-file letter from the FDA for the biologics license application for Molbreevi as a therapy to treat patients with autoimmune pulmonary alveolar proteinosis.The FDA determined the license application, which was submitted in March, was not sufficiently complete and needed additional data on chemistry, manufacturing and controls. The refusal to file was not the result of safety concerns and the FDA did not request additional efficacy studies, Savara said.Savara plans to request a Type A meeting with the FDA within the next 30 days. It is currently generating the data requested by the FDA, and expects to resubmit its application in the fourth quarter of 2025, CHief Executive Matt Pauls said.The letter does not impact previous designations granted ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SVRA":"Savara Inc"},"translate_title":"FDA拒绝药物申请后Savara股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SVRA":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Savara shares fell after the Food and Drug Administration said its drug is not ready for a full review. \n\n\n  The stock dropped 35% to $1.85 in pre-market trading Tuesday. \n\n\n  The Langhorne, Pa., biopharmaceutical company said Tuesday it received a refusal-to-file letter from the FDA for the biologics license application for Molbreevi as a therapy to treat patients with autoimmune pulmonary alveolar proteinosis. \n\n\n  The FDA determined the license application, which was submitted in March, was not sufficiently complete and needed additional data on chemistry, manufacturing and controls. The refusal to file was not the result of safety concerns and the FDA did not request additional efficacy studies, Savara said. \n\n\n  Savara plans to request a Type A meeting with the FDA within the next 30 days. It is currently generating the data requested by the FDA, and expects to resubmit its application in the fourth quarter of 2025, CHief Executive Matt Pauls said. \n\n\n  The letter does not impact previous designations granted by regulators by Molbreevi. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 27, 2025 08:56 ET (12:56 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}